1.00 Back-Tracking Breakthroughs for BITEs & Cell Engagers to Gain Reverse Translation Insights

Time: 1:00 pm
day: Workshop D


Post-approval studies offer a real-world lens on the long-term safety, efficacy, and practical applications of cell engager drugs, providing crucial insights into diverse patient populations and clinical scenarios. By incorporating back translation strategies developers can transform insights into actionable lessons to overcome limited animal models to mimic systemic immune response in patients and improve safety profiles.

  • Discuss perspectives from clinical development leaders and oncologists treating a range patient populations day to day
  • Explore evidence of disease progression and potential immune escape or resistance mechanisms. Do some patients respond better to cell engager therapies?
  • Uncover the long-term effects and explore future avenues for combination therapies